Clear All
11120 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
43602-0176-05 43602-0176 Bexarotene Bexarotene 75.0 mg/1 Hormonal Therapy Immunomodulator Retinoic Acid Derivative Oral Sep 6, 2024 In Use
50242-0933-01 50242-0933 Atezolizumab and hyaluronidase-tqjs Tecentriq Hybreza 1875.0 mg/15mL, 30000.0 U/15mL Immunotherapy Checkpoint Inhibitor PD-L1 Subcutaneous Sep 12, 2024 In Use
50242-0933-86 50242-0933 Atezolizumab and hyaluronidase-tqjs Tecentriq Hybreza 1875.0 mg/15mL, 30000.0 U/15mL Immunotherapy Checkpoint Inhibitor PD-L1 Subcutaneous Sep 12, 2024 In Use
60505-6279-00 60505-6279 Cisplatin CISplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sep 13, 2024 In Use
25021-0471-74 25021-0471 Fulvestrant Fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Sep 15, 2024 In Use
63759-3032-01 63759-3032 Bortezomib Bortezomib 3.5 mg/1.4mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Sep 25, 2024 In Use
69097-0004-67 69097-0004 Hydrocortisone sodium succinate Hydrocortisone sodium succinate 100.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Sep 25, 2024 In Use
70121-2484-01 70121-2484 Bortezomib BORUZU 3.5 mg/1.4mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous Sep 27, 2024 In Use
57237-0078-01 57237-0078 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sep 30, 2024 In Use
83831-0104-05 83831-0104 Palonosetron Posfrea 0.075 mg/1.5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 30, 2024 Sep 30, 2024 No Longer Used
83831-0105-01 83831-0105 Palonosetron Posfrea 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 30, 2024 In Use
57237-0078-50 57237-0078 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Sep 30, 2024 In Use
72603-0325-01 72603-0325 Pemetrexed disodium Pemetrexed 100.0 mg/10mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Oct 1, 2024 In Use
72603-0425-01 72603-0425 Pemetrexed disodium Pemetrexed 500.0 mg/50mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Oct 1, 2024 In Use
00480-9262-08 00480-9262 Octreotide Acetate Octreotide Acetate 3.33 mg/ml Hormonal Therapy Somatostatin Analog Intramuscular Oct 1, 2024 In Use
00480-9259-08 00480-9259 Octreotide Acetate Octreotide Acetate 3.33 mg/ml Hormonal Therapy Somatostatin Analog Intramuscular Oct 1, 2024 In Use
00781-3312-95 00781-3312 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct 1, 2024 In Use
00781-3415-95 00781-3415 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct 1, 2024 In Use
00781-3531-91 00781-3531 Paclitaxel Paclitaxel 100.0 mg/20mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct 9, 2024 In Use
50242-0084-08 50242-0084 Inavolisib Itovebi 3.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K⍺ Oral Oct 14, 2024 In Use
50242-0079-08 50242-0079 Inavolisib Itovebi 9.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K⍺ Oral Oct 14, 2024 In Use
50090-7369-05 50090-7369 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct 18, 2024 In Use
00310-9501-02 00310-9501 Capivasertib TRUQAP 200.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use
50090-7369-00 50090-7369 Prednisone Prednisone 10.0 mg/1 Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Oral Oct 18, 2024 In Use
00310-9500-02 00310-9500 Capivasertib TRUQAP 160.0 mg/1 Chemotherapy AKT Inhibitor AKT1/2/3 Oral Oct 18, 2024 In Use

Found 11120 results — Export these results